Ongoing Clinical Trials

TYPE OF CANCERTITLEHOSPITALPRINCIPAL INVESTIGATORSUB INVESTIGATORCONTACT PERSONRECRUITING UNTIL
BladderA Phase III, Randomized, Open-label, Multi-center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)VMMCDr. JP Querol
BladderA Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standar of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)VMMCDr. JP Querol
BreastA randomized double blind parallel group phase III trial to compare the effocacy safety and immunogenicity of TX05 with herceptin in subjects with her2 positive early breast cancerSLMC PGH VMMCDr. PB Caguioa Dr. IO Real Dr. AB Ong-CornelDr. Cyrielle Atutubo (SLMC)
BreastA phase III Randomized, double – blind study of PF – 05280014 plusVMMC
BreastPaclitaxel versus trastuzumab plus paclitaxel for the First Line Treatment of patients with Her 2 positive Metastatic Breast Cancer. VMMC
GastricA Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel with or withour Ramucirumab (IMC-1121B) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive after First-Line Therapy with Platinum and FluropyrimidineDLSUMCDr. PD Santos
LiverA Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Reximmune-C2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes) in Refractory Patients with Primary Hepatocellular Carcinoma or Tumours metastatic to the Liver.TMC NKTI SLMC-QCDr. JP Querol Dr. NS Juat Dr. PB CaguioaDr. Joanmarie Balolong-Garcia
LungMulticenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung CancerPGHDr. JG Ignacio
LungSTELLA – A Randomized, Multicenter, Multinational, Double-Blind  Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)PGH SLMC-QCDr. JB Sandoval-Tan Dr. PB Caguioa
LungA Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)USTH VMMCDr. T Sy Ortin Dr. AB Ong-CornelDr. PB Caguioa Dr. EEV Regala Dr. JA TapispisanMs. Maricon - 0918 962 7266
LungA Global, Randomized, Phase 3, Open-label Study of REGN2810 (Anti-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients with Advance or Metastatic PD L1 + Non-Small Cell Lung Cancer (R2810-ONC-1624)VMMCDr. AB Ong-Cornel
LymphomaA Phase III, randomized, double-blind, placebo controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’ lymphoma (iNHL).PGHDr. JB Sandoval-Tan
LymphomaA Randomized, Open-Label, Multi-Center Study to Evaluate Patient Preference with Subcutaneous Administration of Rituximab versus Intravenous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2 or 3A (PrefMab)PGHDr. JB Sandoval-Tan
OvarianClinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study